In this second patient case video from BREAST CANCER CONNECT, Prof. Maria Vittoria Dieci delves into the continuation of a patient case with ER+/HER2- metastatic breast cancer initially presented in our first video of this series.
Throughout this journey, we'll explore what to expect after prescribing elacestrant and take a closer look at patient-reported outcomes in the EMERALD trial.
Catch up on the first video to hear Prof Francois-Clement Bidard discuss how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer.
Clinical Takeaways
-
PROs results demonstrating no difference between treatment arms in the EMERALD trial, support elacestrant as a clinically meaningful option in this setting
-
Elacestrant has a manageable safety profile
-
If a patient progresses on elacestrant, the choice of subsequent therapy line should be based on multiple factors, including sensitivity to prior treatments, disease burden, and tumour biology. In this context, ADCs represent a new option
Download Slides - PPT 
Duration
Language(s)
1 MIN
May 2025 
Downloadable 
